AN2 Therapeutics Inc
NASDAQ:ANTX

Watchlist Manager
AN2 Therapeutics Inc Logo
AN2 Therapeutics Inc
NASDAQ:ANTX
Watchlist
Price: 1.1 USD 2.8%
Market Cap: 30.1m USD

Relative Value

There is not enough data to reliably calculate the relative value of ANTX.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ANTX Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.6
vs History
vs Industry
Median 3Y
-1
Median 5Y
-2
Industry
21.4
Forward
-1
vs History
vs Industry
Median 3Y
-1.2
Median 5Y
-2.5
Industry
16.4
vs History
vs Industry
Median 3Y
-1.2
Median 5Y
-2.5
Industry
22.8
vs History
74
vs Industry
74
Median 3Y
0.7
Median 5Y
0.9
Industry
2.2
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.9
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.5
vs History
12
vs Industry
53
Median 3Y
0.6
Median 5Y
-0.3
Industry
13
vs History
12
vs Industry
51
Median 3Y
0.6
Median 5Y
-0.3
Industry
16.5
Forward
0.9
vs History
4
vs Industry
54
Median 3Y
0.7
Median 5Y
-0.3
Industry
15.6
vs History
4
vs Industry
41
Median 3Y
0.7
Median 5Y
-0.3
Industry
18.7
vs History
vs Industry
55
Median 3Y
-3.2
Median 5Y
-3.2
Industry
1.9

Multiples Across Competitors

ANTX Competitors Multiples
AN2 Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
AN2 Therapeutics Inc
NASDAQ:ANTX
30.1m USD 0 -0.9 0.9 0.9
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.6 56.7 38 40.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
498.5B USD 5.4 19.8 16.2 21.1
CH
Roche Holding AG
SIX:ROG
268.8B CHF 4.4 28.5 12.1 14.2
UK
AstraZeneca PLC
LSE:AZN
219.6B GBP 5.1 31.5 108.7 159.1
US
Merck & Co Inc
NYSE:MRK
277.5B USD 4.3 14.6 10.3 12.2
CH
Novartis AG
SIX:NOVN
219.4B CHF 4.9 19.1 12.1 15.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.2 15.8 11 12.8
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
144.8B USD 2.3 14.7 7.5 10.2
P/E Multiple
Earnings Growth PEG
US
AN2 Therapeutics Inc
NASDAQ:ANTX
Average P/E: 25.1
Negative Multiple: -0.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
56.7
54%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.8
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.5
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.5
37%
0.9
US
Merck & Co Inc
NYSE:MRK
14.6
15%
1
CH
Novartis AG
SIX:NOVN
19.1
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
15.8
3%
5.3
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.7
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
AN2 Therapeutics Inc
NASDAQ:ANTX
Average EV/EBITDA: 400.2
0.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.2
9%
1.8
CH
Roche Holding AG
SIX:ROG
12.1
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.7
10%
10.9
US
Merck & Co Inc
NYSE:MRK
10.3
6%
1.7
CH
Novartis AG
SIX:NOVN
12.1
6%
2
DK
Novo Nordisk A/S
CSE:NOVO B
11
1%
11
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
AN2 Therapeutics Inc
NASDAQ:ANTX
Average EV/EBIT: 1 712.6
0.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
40.7
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.1
15%
1.4
CH
Roche Holding AG
SIX:ROG
14.2
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.1
23%
6.9
US
Merck & Co Inc
NYSE:MRK
12.2
8%
1.5
CH
Novartis AG
SIX:NOVN
15.6
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
12.8
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5